OTCMKTS:BRRGF BerGenBio ASA (BRRGF) Stock Forecast, Price & News $1.77 0.00 (0.00%) (As of 05/12/2023) Add Compare Share Share Today's Range$1.77▼$1.7750-Day Range$1.77▼$1.7752-Week Range$1.77▼$2.35VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About BerGenBio ASA (OTCMKTS:BRRGF) StockBerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.Read More BRRGF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRRGF Stock News HeadlinesAugust 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)August 22, 2023 | finance.yahoo.comBerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 15, 2023 | bbc.co.ukCoronation concert ballot misleading, says regulator ASAMay 26, 2023 | finance.yahoo.comBerGenBio ASA: Approval and publication of prospectus for the preferential Rights IssueMay 16, 2023 | markets.businessinsider.comBerGenBio AS (BRRGF) Gets a Buy from H.C. WainwrightApril 25, 2023 | finance.yahoo.comBerGenBio ASA: Proposed partially underwritten rights issueMarch 9, 2023 | finance.yahoo.comBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 17, 2023 | finanznachrichten.deBerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsFebruary 16, 2023 | finance.yahoo.comBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateFebruary 15, 2023 | finance.yahoo.comBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsNovember 15, 2022 | finance.yahoo.comBerGenBio reports third quarter 2022 financial results and provides business updateOctober 25, 2022 | prnewswire.comBerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASOctober 11, 2022 | finance.yahoo.comBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsSeptember 27, 2022 | finance.yahoo.comBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSSeptember 10, 2022 | reuters.comBGBIO.OL - Bergenbio ASA | Stock Price & Latest News | ReutersAugust 23, 2022 | finance.yahoo.comBerGenBio reports second quarter and half year 2022 financial results and provides business updateApril 11, 2022 | finance.yahoo.comBerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical OfficerApril 7, 2022 | finance.yahoo.comBERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021February 16, 2022 | finance.yahoo.comBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021January 27, 2022 | finance.yahoo.comBerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 PatientsJanuary 21, 2022 | nasdaq.comBRRGF Real-Time QuotesJanuary 18, 2022 | nasdaq.comBRRGF Price/Earnings & PEG RatiosNovember 9, 2021 | finance.yahoo.comBergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021November 9, 2021 | finance.yahoo.comBerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)July 12, 2021 | finance.yahoo.comBerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMIDSee More Headlines Receive BRRGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BRRGF CUSIPN/A CIKN/A Webwww.bergenbio.com Phone47 53 50 15 64FaxN/AEmployees28Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Martin Olin (Age 54)Chief Exec. Officer Comp: $863.23kMr. Rune Skeie (Age 50)Chief Financial Officer Comp: $235.5kDr. James Barnes Ph.D.Chief Operating OfficerMs. Gayle M. Mills M.B.A (Age 68)Chief Bus. Officer Ms. Cristina Oliva M.D.Chief Medical OfficerGraham MorellHead of IRDr. Akil JacksonMedical DirectorMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees Pharmaceuticals, Inc. WarrantNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAbliva AB (publ)OTCMKTS:NEVPFAdociaOTCMKTS:ADOIFView All Competitors BRRGF Stock - Frequently Asked Questions Should I buy or sell BerGenBio ASA stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BRRGF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRRGF, but not buy additional shares or sell existing shares. View BRRGF analyst ratings or view top-rated stocks. How have BRRGF shares performed in 2023? BerGenBio ASA's stock was trading at $1.77 at the start of the year. Since then, BRRGF shares have increased by 0.0% and is now trading at $1.77. View the best growth stocks for 2023 here. Are investors shorting BerGenBio ASA? BerGenBio ASA saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 241,000 shares, a decrease of 90.2% from the August 15th total of 2,463,000 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 1,205.0 days. View BerGenBio ASA's Short Interest. What is BerGenBio ASA's stock symbol? BerGenBio ASA trades on the OTCMKTS under the ticker symbol "BRRGF." How do I buy shares of BerGenBio ASA? Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BerGenBio ASA's stock price today? One share of BRRGF stock can currently be purchased for approximately $1.77. How can I contact BerGenBio ASA? BerGenBio ASA's mailing address is Jonas Lies Vei 91, Bergen, Hordaland 5009. The official website for the company is www.bergenbio.com. The company can be reached via phone at 47 53 50 15 64. This page (OTCMKTS:BRRGF) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BerGenBio ASA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.